Related Experiment Video
Updated: Apr 1, 2026
Standardized Data Acquisition for Neuromelanin-Sensitive Magnetic Resonance Imaging of the Substantia Nigra
Published on: September 8, 2021
A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression
Molly A Erickson1, Abigail Ruffle1, James M Gold1
1Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, Maryland.
Background:
The observation that mismatch negativity (MMN) is consistently impaired in schizophrenia has generated considerable interest in the use of this biomarker as an index of disease risk and progression. Despite such enthusiasm, a number of issues remain unresolved regarding the nature of MMN impairment. The present study expands upon an earlier meta-analysis of MMN impairment in schizophrenia by examining impairment across a range of clinical presentations, as well as across experimental parameters.
Methods:
One hundred one samples of schizophrenia patients were included in the present study, including first-episode (n = 13), chronic (n = 13), and mixed-stage (n = 75) samples. Additionally, MMN was examined in three related conditions: bipolar disorder (n = 9), unaffected first-degree relatives (n = 8), and clinical high risk (n = 16).
Results:
We found that MMN impairment 1) likely reflects a vulnerability to disease progression in clinical high-risk populations rather than a genetic risk for the condition; 2) is largely unrelated to duration of illness after the first few years of illness, indicating that impairment is not progressive throughout the life span; 3) is present in bipolar disorder, albeit to a lesser degree than in schizophrenia; and 4) is not modulated by experimental parameters such as magnitude of change between standard and deviant tones or frequency of deviant tones but may be modulated by attentional demands.
Conclusions:
Such findings lay the foundation for a better understanding of the nature of MMN impairment in schizophrenia, as well as its potential as a clinically useful biomarker.
Insights
Mismatch negativity (MMN) impairment in schizophrenia may indicate vulnerability to disease progression, not genetic risk. This auditory biomarker is not significantly affected by illness duration or experimental factors, offering potential clinical utility.
Area of Science:
- Neuroscience
- Psychiatry
- Biomarker Research
Background:
- Mismatch negativity (MMN) is a neurophysiological auditory evoked potential consistently found to be impaired in schizophrenia.
- Its potential as a biomarker for disease risk and progression is of significant interest, but requires further clarification.
- Previous meta-analyses have explored MMN impairment in schizophrenia, necessitating expanded research across diverse clinical and experimental contexts.
Purpose of the Study:
- To investigate the nature of MMN impairment in schizophrenia across various clinical presentations and experimental parameters.
- To examine MMN in related conditions, including bipolar disorder, unaffected relatives, and clinical high-risk populations.
- To clarify the utility of MMN as a biomarker for schizophrenia risk and progression.
Main Methods:
- A meta-analysis including 101 schizophrenia patient samples (first-episode, chronic, mixed-stage).
- MMN was also assessed in 9 bipolar disorder patients, 8 unaffected first-degree relatives, and 16 individuals at clinical high risk.
- Analysis considered clinical presentations and experimental parameters like tone change magnitude and frequency.
Main Results:
- MMN impairment appears to reflect vulnerability to disease progression in high-risk groups, rather than a direct genetic risk.
- Impairment is largely stable after the initial years of illness, suggesting it is not progressively worsening.
- MMN deficits are present in bipolar disorder, though less pronounced than in schizophrenia.
- Experimental parameters did not significantly modulate MMN, but attentional demands may play a role.
Conclusions:
- MMN impairment in schizophrenia is linked to disease progression vulnerability, not solely genetic predisposition.
- The findings support MMN's potential as a clinical biomarker, particularly for identifying those at risk.
- Further research can refine understanding and application of MMN in psychiatric disorders.
More Related Videos
13:08Measurement of Fronto-limbic Activity Using an Emotional Oddball Task in Children with Familial High Risk for Schizophrenia
Published on: December 2, 2015
05:52Handwriting Analysis Indicates Spontaneous Dyskinesias in Neuroleptic Naïve Adolescents at High Risk for Psychosis
Published on: November 21, 2013
Related Concept Videos
01:29Psychological and Sociocultural Causes of Schizophrenia
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...
01:36Mismatch Repair
01:29Biological Causes of Schizophrenia
Genetic Factors in Schizophrenia
The genetic basis of schizophrenia is strongly supported by family and twin...
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
01:30Negative and Cognitive Symptoms of Schizophrenia
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...